# BLASST-1 (NCT03294304)

> BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03294304
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Masonic Cancer Center, University of Minnesota
- Conditions: Muscle Invasive Bladder Cancer
- Interventions: Nivolumab; Cisplatin; Gemcitabine
- Enrollment: 43
- Primary outcome: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging to ≤pT1pN0 Which Includes pT0, pT1, pTa and pTis)

## Indexed commentary on BLASST-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 13
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=blasst-1-nct03294304

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03294304", "email": "<work email>"}; the inbox owner confirms by the emailed link.